newsfilter
← Latest News
SoftBank Vision Fund·

Hugo de Wit: Building futuristic tools to deepen cellular understanding

Summary

  • LUMICKS, founded in 2014 in Amsterdam, develops advanced tools combining physics, biology, & engineering to observe molecular interactions in real time for drug safety & efficacy testing.
  • The initial V1 C-Trap Optical Tweezers platform required significant customization by biophysicists & faced usability challenges that limited broader adoption.
  • A deep listening exercise with users led to the development of a V2 platform designed for plug-and-play automation to serve biologists & expand market potential.
  • The C-Trap uses dual laser beams to stretch & bend DNA, allowing scientists to film protein movements & binding dynamics previously impossible to measure.
  • After selling its first unit in 2016, the company spent two years refining workflows & coaching users to gain traction beyond its original biophysics niche.
  • Customer feedback revealed needs for new applications like nuclear extract analysis & measuring cell binding forces for cancer cell therapies.
  • The company now targets pharma partners for DNA & gene-based medicine discovery by offering faster, simpler, & more usable data on cell binding forces.
  • CEO Hugo de Wit emphasizes pivoting from technical exploration to customer-driven exploitation immediately after the first sale to avoid growth stagnation.
  • Leadership challenges include integrating diverse disciplines, scaling teams with marketing & sales roles, & maintaining collaboration while building complex products rapidly.

Hugo de Wit shares how customer feedback shaped the C-Trap optical tweezers. Discover biotech innovation driven by consumer & market insights.

Keywords
Strategy